Larvol Delta - ProLynx-announces-Phase-1B-clinical-trial-of-its-DNAdamaging-agent-PLX038-PEGSN38-with-the-PARP-inhibitor-Rubraca174-rucaparib-at-the-National-Cancer-Institute-160

Rubraca (rucaparib) - Clovis

firtecan pegol (PEG-SN38) - Zhejiang Hisun, Belrose

http://www.globenewswire.com/news-release/2020/04/13/2015055/0/en/ProLynx-announces-Phase-1B-clinical-trial-of-its-DNA-damaging-agent-PLX038-PEG-SN-38-with-the-PARP-inhibitor-Rubraca-rucaparib-at-the-National-Cancer-Institute.html

Apr 13, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next